Literature DB >> 19140219

Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells.

Jun Wu1, Zhongji Meng, Min Jiang, Rongjuan Pei, Martin Trippler, Ruth Broering, Agnes Bucchi, Jan-Peter Sowa, Ulf Dittmer, Dongliang Yang, Michael Roggendorf, Guido Gerken, Mengji Lu, Joerg F Schlaak.   

Abstract

UNLABELLED: We have previously shown that Toll-like receptor (TLR)-activated murine nonparenchymal liver cells [(NPC); Kupffer cells (KC), liver sinusoidal endothelial cells (LSEC)] can suppress hepatitis B virus (HBV) replication. Therefore, the aim of this study was to investigate whether HBV has the ability to counteract the TLR-mediated control of its replication. Freshly purified murine hepatocytes and NPCs obtained from C57BL6 mice were stimulated by TLR 1-9 ligands in the presence or absence of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), HBV virions, or supernatants from HBV-producing HBV-Met cells, and HBV replication was suppressed by anti- hepatitis B virus X protein (HBx) small interfering RNA (siRNA) in HBV-Met cells. Supernatants were collected and tested for antiviral cytokines by viral protection assay. HBV gene expression and replication was analyzed by southern blot. RNA and proteins were analyzed by quantitative reverse transcription polymerase chain reaction (RT-PCR) or western blot and enzyme-linked immunosorbent assay, respectively. Pretreatment of hepatocytes and NPCs with HBV-Met cells supernatants, HBsAg, HBeAg, or HBV virions almost completely abrogated TLR-induced antiviral activity, which correlated with suppression of interferon beta (IFN-beta) production and subsequent interferon-stimulated gene induction as well as suppressed activation of interferon regulatory factor 3 (IRF-3), nuclear factor kappa B (NF-kappaB), and extracellular signal-regulated kinase (ERK) 1/2. In HBV-infected HBV-Met cells, TLR stimulation did not induce antiviral cytokines in contrast to primary hepatocytes. TLR-stimulated expression of proinflammatory cytokines [tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6)], and activation of IRF-3 was suppressed after up-regulation of HBV replication in HBV-Met cells. Accordingly, suppression of HBV replication by siRNA led to activation or expression of proinflammatory transcription factors and cytokines.
CONCLUSION: Our data indicate that HBV can suppress the TLR-induced antiviral activity of liver cells. This has major implications for the interaction between HBV and the immune system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19140219     DOI: 10.1002/hep.22751

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  114 in total

1.  An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases.

Authors:  Jieliang Chen; Wen Zhang; Junyu Lin; Fan Wang; Min Wu; Cuncun Chen; Ye Zheng; Xiuhua Peng; Jianhua Li; Zhenghong Yuan
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

2.  Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication.

Authors:  Guangyun Tan; Qingfei Xiao; Hongxiao Song; Feng Ma; Fengchao Xu; Di Peng; Na Li; Xiaosong Wang; Junqi Niu; Pujun Gao; F Xiao-Feng Qin; Genhong Cheng
Journal:  Cell Mol Immunol       Date:  2017-02-13       Impact factor: 11.530

3.  Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO.

Authors:  Yuan Wang; Lei Cui; Guifang Yang; Jianbo Zhan; Liang Guo; Yu Chen; Chengpeng Fan; Dan Liu; Deyin Guo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 4.  Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.

Authors:  Jieliang Chen; Zhenghong Yuan
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

Review 5.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

Review 6.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

7.  Molecular mechanisms of HBeAg in persistent HBV infection.

Authors:  Li-Min Chen; Xue-Gong Fan; Jing Ma; Bo He; Yong-Fang Jiang
Journal:  Hepatol Int       Date:  2016-05-18       Impact factor: 6.047

Review 8.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

9.  Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion.

Authors:  Haifeng Wang; Wang-Shick Ryu
Journal:  PLoS Pathog       Date:  2010-07-15       Impact factor: 6.823

10.  Importance of TLR2 on hepatic immune and non-immune cells to attenuate the strong inflammatory liver response during Trypanosoma cruzi acute infection.

Authors:  Eugenio Antonio Carrera-Silva; Natalia Guiñazu; Andrea Pellegrini; Roxana Carolina Cano; Alfredo Arocena; Maria Pilar Aoki; Susana Gea
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.